Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab...
VANCOUVER, British Columbia & SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 5, 2021-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biothe...